242 related articles for article (PubMed ID: 28893290)
1. Evasion of adaptive immunity by HIV through the action of host APOBEC3G/F enzymes.
Grant M; Larijani M
AIDS Res Ther; 2017 Sep; 14(1):44. PubMed ID: 28893290
[TBL] [Abstract][Full Text] [Related]
2. APOBEC3G Regulation of the Evolutionary Race Between Adaptive Immunity and Viral Immune Escape Is Deeply Imprinted in the HIV Genome.
Borzooee F; Joris KD; Grant MD; Larijani M
Front Immunol; 2018; 9():3032. PubMed ID: 30687306
[TBL] [Abstract][Full Text] [Related]
3. Positioning of APOBEC3G/F mutational hotspots in the human immunodeficiency virus genome favors reduced recognition by CD8+ T cells.
Monajemi M; Woodworth CF; Zipperlen K; Gallant M; Grant MD; Larijani M
PLoS One; 2014; 9(4):e93428. PubMed ID: 24722422
[TBL] [Abstract][Full Text] [Related]
4. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
5. Apobec3G-Based Strategies to Defeat HIV Infection.
Ran X; Ao Z; Yao X
Curr HIV Res; 2016; 14(3):217-24. PubMed ID: 26957196
[TBL] [Abstract][Full Text] [Related]
6. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.
Casartelli N; Guivel-Benhassine F; Bouziat R; Brandler S; Schwartz O; Moris A
J Exp Med; 2010 Jan; 207(1):39-49. PubMed ID: 20038599
[TBL] [Abstract][Full Text] [Related]
7. Strategy of Human Cytomegalovirus To Escape Interferon Beta-Induced APOBEC3G Editing Activity.
Pautasso S; Galitska G; Dell'Oste V; Biolatti M; Cagliani R; Forni D; De Andrea M; Gariglio M; Sironi M; Landolfo S
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045985
[TBL] [Abstract][Full Text] [Related]
8. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
Han Y; Wang X; Dang Y; Zheng YH
PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
[TBL] [Abstract][Full Text] [Related]
9. Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment.
Monajemi M; Woodworth CF; Benkaroun J; Grant M; Larijani M
Retrovirology; 2012 Apr; 9():35. PubMed ID: 22546055
[TBL] [Abstract][Full Text] [Related]
10. APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.
Mbisa JL; Bu W; Pathak VK
J Virol; 2010 May; 84(10):5250-9. PubMed ID: 20219927
[TBL] [Abstract][Full Text] [Related]
11. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA; Pathak VK
J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
[TBL] [Abstract][Full Text] [Related]
12. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets.
Koning FA; Newman EN; Kim EY; Kunstman KJ; Wolinsky SM; Malim MH
J Virol; 2009 Sep; 83(18):9474-85. PubMed ID: 19587057
[TBL] [Abstract][Full Text] [Related]
13. The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F.
Hu C; Saenz DT; Fadel HJ; Walker W; Peretz M; Poeschla EM
J Virol; 2010 Nov; 84(22):11981-93. PubMed ID: 20844042
[TBL] [Abstract][Full Text] [Related]
14. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
[TBL] [Abstract][Full Text] [Related]
15. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
16. DNA mutagenic activity and capacity for HIV-1 restriction of the cytidine deaminase APOBEC3G depend on whether DNA or RNA binds to tyrosine 315.
Polevoda B; Joseph R; Friedman AE; Bennett RP; Greiner R; De Zoysa T; Stewart RA; Smith HC
J Biol Chem; 2017 May; 292(21):8642-8656. PubMed ID: 28381554
[TBL] [Abstract][Full Text] [Related]
17. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
[TBL] [Abstract][Full Text] [Related]
18. Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression.
Amoêdo ND; Afonso AO; Cunha SM; Oliveira RH; Machado ES; Soares MA
PLoS One; 2011; 6(8):e24118. PubMed ID: 21897871
[TBL] [Abstract][Full Text] [Related]
19. The effect of HIV-1 Vif polymorphisms on A3G anti-viral activity in an in vivo mouse model.
Cadena C; Stavrou S; Manzoni T; Iyer SS; Bibollet-Ruche F; Zhang W; Hahn BH; Browne EP; Ross SR
Retrovirology; 2016 Jun; 13(1):45. PubMed ID: 27363431
[TBL] [Abstract][Full Text] [Related]
20. Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1.
Apolonia L; Schulz R; Curk T; Rocha P; Swanson CM; Schaller T; Ule J; Malim MH
PLoS Pathog; 2015 Jan; 11(1):e1004609. PubMed ID: 25590131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
